Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Hillhouse Investment Management10% Owner | ArriVent BioPharmaAVBP | Open-market sale | 25/12/10 | 02/03 | 555,555 sh | $23.37 | $12,983,320.35 | −12.4% |
Hhlr Advisors Ltd.10% Owner | ArriVent BioPharmaAVBP | Open-market sale | 25/12/10 | 02/03 | 555,555 sh | $23.37 | $12,983,320.35 | −12.4% |
Hillhouse Investment Management10% Owner | ArriVent BioPharmaAVBP | Open-market buy | 24/01/30 | 24/02/01 | 555,555 sh | $18.00 | $9,999,990 | +14.1% |
Hhlr Advisors Ltd.10% Owner | ArriVent BioPharmaAVBP | Open-market buy | 24/01/30 | 24/02/01 | 555,555 sh | $18.00 | $9,999,990 | +14.1% |
ArriVent BioPharmaAVBP | Open-market buy | 24/01/30 | 24/01/31 | 444,444 sh2 trades | $18.00avg. | $7,999,992 | +41.6% | |
James HealyDirector | ArriVent BioPharmaAVBP | Open-market buy | 24/01/30 | 24/01/31 | 444,444 sh | $18.00 | $7,999,992 | +35.5% |
Director | ArriVent BioPharmaAVBP | Open-market buy | 24/01/30 | 24/01/31 | 444,444 sh2 trades | $18.00avg. | $7,999,992 | +41.6% |
ArriVent BioPharmaAVBP | Open-market buy | 24/01/30 | 24/01/31 | 444,444 sh2 trades | $18.00avg. | $7,999,992 | +41.6% | |
ArriVent BioPharmaAVBP | Open-market buy | 24/01/30 | 24/01/31 | 444,444 sh2 trades | $18.00avg. | $7,999,992 | +41.6% | |
ArriVent BioPharmaAVBP | Open-market buy | 24/01/30 | 24/01/31 | 444,444 sh2 trades | $18.00avg. | $7,999,992 | +41.6% |
